desvenlafaxine succinate sustained release (DVS SR)
Phase 1Completed 0 watching 0 views this week๐ค Quiet
32
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Vasomotor Symptoms
Conditions
Vasomotor Symptoms
Trial Timeline
Nov 1, 2006 โ Feb 1, 2007
NCT ID
NCT00397176About desvenlafaxine succinate sustained release (DVS SR)
desvenlafaxine succinate sustained release (DVS SR) is a phase 1 stage product being developed by Pfizer for Vasomotor Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT00397176. Target conditions include Vasomotor Symptoms.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00397176 | Phase 1 | Completed |
Competing Products
20 competing products in Vasomotor Symptoms